Nutrition

Researchers are investigating whether a multifactorial lifestyle intervention involving a Mediterranean diet with reduced calories and increased physical activity can help middle-aged adults 30-50 years with metabolic syndrome lose weight and maintain that weight loss over time. The study also aims to understand the social and demographic challenges people face in sticking to these healthy habits and to examine the lifestyle patterns of this group. Participants will be randomly assigned to one of two groups. One group will follow general lifestyle recommendations from primary healthcare providers, while the other will receive an intensive program that includes monthly individual and group sessions over 6 months to encourage a Mediterranean diet with 25% fewer calories and physical activity based on WHO guidelines. The goal for the intervention group is to reduce their initial weight by 5-10% within 6 months and maintain this loss after 12 months. Throughout the study, participants will undergo assessments including measurements of weight, waist size, blood sugar, triglycerides, and glycated hemoglobin to monitor changes in their health. Data on demographics, diet, clinical parameters, and laboratory tests will be collected. After the 6-month intervention, a follow-up at 12 months will evaluate how well participants maintain their lifestyle changes. The study emphasizes tracking adherence and identifying factors that help or hinder long-term weight loss maintenance.

Researchers are working to create risk prediction models that help identify patients with a high risk of developing serious cardiovascular problems. The study focuses on individuals with structural, rhythm-related, or inflammatory cardiovascular diseases and aims to improve early detection of those at risk. This observational study is sponsored by the Medical University Innsbruck and includes adults 18 years and older. Participants in this study have their clinical data and risk factors recorded to better understand their cardiovascular condition. There are no specific treatments or interventions given as part of the study since it is observational. The study will follow patients for up to four years to observe outcomes related to cardiovascular events and hospitalizations. During the study, researchers will monitor events such as cardiovascular mortality, stroke, heart attacks, hospital stays due to heart failure, and other severe heart-related conditions. Participants will be assessed regularly through clinical data collection without additional procedures or treatments. The study aims to gather detailed information over time to improve risk assessment and patient care for cardiovascular diseases.

Researchers are evaluating the effects of the traditional Vietnamese Xuong tan lac than exercise on joint range of motion and muscle endurance in healthy adults. This study aims to determine if practicing this exercise improves movement and muscle endurance around multiple joints including the cervical spine, lumbar spine, shoulders, elbows, wrists, knees, and ankles. The study focuses on healthy volunteers and explores how this traditional exercise may support musculoskeletal function. Participants will be trained to correctly perform the Xuong tan lac than exercise, which involves a series of breathing and controlled lateral trunk movements while standing in a semi-squat position. They will practice the exercise once daily, five days a week, for 12 weeks, following a standardized protocol. Assessments will be conducted at the start and after 2, 4, 8, and 12 weeks to track changes. Throughout the study, participants will undergo measurements of joint range of motion using the Noraxon MyoMotion system with inertial measurement sensors, as well as tests of muscle endurance. Researchers will assess nerve conduction parameters at the beginning and end of the study. These evaluations aim to capture improvements in joint mobility and muscle function over the 12-week exercise program. The study involves regular monitoring and adherence to the exercise schedule under research supervision.

This research aims to compare the effectiveness of monitoring blood sugar levels at 1 hour versus 2 hours after meals in pregnant women diagnosed with Gestational Diabetes Mellitus who require treatment. The study focuses on understanding which monitoring time better supports managing blood sugar during pregnancy to improve outcomes for both mother and baby. Participants are pregnant women attending an antenatal clinic and are treated with metformin, insulin, or a combination. Participants will be randomly assigned to monitor their blood sugar either 1 hour or 2 hours after meals using self-monitoring of capillary blood glucose. Their blood sugar is tracked at seven staggered points to provide a detailed profile. This monitoring continues until delivery, with participants followed regularly in the research clinic. Throughout the study, women will have regular visits to assess their health and that of their baby. Researchers will collect data on mode of delivery, gestational age at birth, and fetal weight. They will also monitor maternal and perinatal complications from randomization to delivery. The total participation lasts from enrollment until the birth of the baby, allowing detailed observation of pregnancy outcomes related to the glucose monitoring method.

Researchers are studying a medicine called MK-8527 to understand how it behaves in the bodies of healthy adults aged 18 to 55. The study aims to learn how MK-8527 interacts when taken with food or combined with other medicines like probenecid and itraconazole. The goal is also to assess the safety of MK-8527 and whether participants can tolerate it without needing to stop due to health issues. Participants will receive single doses of MK-8527 under different conditions with food and without food, alone and combined with probenecid, and alone and combined with itraconazole. This crossover study allows each participant to experience all these dosing scenarios to compare how the medicine behaves in each case. During the study, participants will be monitored through blood and urine tests at specified times up to 336 hours after dosing to measure MK-8527 levels and its clearance. Researchers will also track any side effects or reasons for stopping treatment over approximately 43 days. The study is conducted by Merck Sharp & Dohme LLC and is expected to complete in October 2026.

The GENESIS clinical study aims to map HLA genetic variation in the Greek population and evaluate possible correlations with selected underlying diseases. It is a multicenter, prospective, non-interventional clinical study targeting 12,000 subjects over an anticipated duration of 36 months, with the goal of creating a pilot HLA map for medical research and possible clinical applications. Each subject will complete one visit at a participating site and provide demographic information, including date of birth, gender, race, ancestry, height, and weight, as well as information about smoking or vaping, alcohol consumption, arterial blood pressure, diagnosed diseases, and current treatments. Recent clinical laboratory results from up to 12 months before sample collection may also be collected when available, including blood count, metabolic, liver enzyme, and biochemical parameters. Two buccal swabs will be collected from each subject for DNA extraction and HLA genotyping analysis. Selected DNA samples will also undergo low-pass whole genome sequencing to further investigate associations between the HLA region and autoimmune diseases. After the analysis is completed, an individualized ancestry report will be securely available to study subjects if they elect to access it.

Researchers are evaluating two medicines, enlicitide and rosuvastatin, in healthy adults aged 18 to 55 years. The study aims to compare the amounts of these medicines in the body over time when given separately and when combined into a single tablet. This research is a Phase 1 trial focused on basic science to understand how these drugs behave when taken together or alone. Participants will receive either a single dose of enlicitide with rosuvastatin tablets taken together or a single dose of a combined tablet called MK-0616A or its formulation B. The study includes two parts where these treatments are given in a randomized crossover design, meaning participants receive different treatments in sequence to compare drug absorption. During the study, participants will be monitored for drug levels in their blood at specific times up to 168 hours after dosing. Researchers will measure how much of each drug is present over time and the highest concentration reached. Safety will also be evaluated by tracking any side effects or adverse events during the approximately nine weeks of observation. Participants will have scheduled visits for dosing and blood sampling throughout the study period.

Researchers are studying a new oral medicine called MK-4082, designed for weight loss in people with higher body weight. This trial focuses on healthy adults to understand how MK-4082 behaves in the body over time. The study also compares MK-4082 levels when taken alone and when combined with another medicine called diltiazem, while checking safety and tolerance. Participants go through two parts in this study. In Part 1, they receive a single oral dose of MK-4082 alone, then a single oral dose of MK-4082 combined with multiple doses of diltiazem. In Part 2, participants receive either a single dose of MK-4082 or a placebo. Ondansetron is provided as a rescue medication to help prevent nausea or vomiting. During the study, participants are monitored for drug levels in their blood at specific times up to about one week after dosing. Researchers also track any adverse events, including whether participants stop treatment due to side effects. The study measures include maximum drug concentration and how long the drug stays in the body. Overall participation lasts several weeks, with assessments during and after dosing to ensure safety and collect data.

Researchers are studying the effects of AP-Brain collagen peptide on attention, focus, stress, and memory in adults aged 35 to 70 who are stressed but otherwise healthy. The study aims to find out how different doses of AP-Brain affect brain function and to identify any side effects. The trial is a randomized, open-label, parallel design sponsored by Rousselot BVBA. Participants will take either a low dose one 1g tablet or a higher dose three 1g tablets of bovine-based AP-Brain collagen peptide once daily for 56 days. The study includes two groups receiving these different doses to compare their effects on cognitive abilities and stress levels. During the study, participants will visit the study center regularly for checkups. They will complete tests that measure attention, focus, and memory and answer surveys about stress. Blood samples will be collected, vital signs checked, and brain responses monitored to understand the impact of AP-Brain. The main outcome focuses on changes in attention and focus after 56 days of treatment.

Researchers are evaluating the effects of Diaberine, a berberine-based nutraceutical, on blood sugar regulation and metabolism in adults with metabolism disorder. This randomized, triple-blind, placebo-controlled trial will study 80 participants aged 18 to 70 over 24 weeks to assess how well this dietary supplement may aid in these health areas. Participants will be randomly assigned to one of two groups. One group will take Diaberine capsules containing Vitamin B12, berberine, magnesium citrate, cinnamon bark extract, chromium, and other ingredients three times daily, 15 minutes before meals. The other group will take placebo capsules with similar appearance but without the active ingredients. Both treatments will continue for 24 weeks with regular monitoring. During the study, participants will have their blood sugar regulation and metabolism measured at baseline, week 12, and week 24. Additionally, quality of life and weight changes will be tracked at multiple points throughout the 24 weeks. Participants will be monitored through questionnaires, blood tests, and weight assessments to evaluate the supplements effects and tolerance over time.